Skip to main content

Advertisement

SpringerLink
Log in

Prior treatment with the tyrosine kinase inhibitors dasatinib and nilotinib allows stem cell transplantation (SCT) in a less advanced disease phase and does not increase SCT Toxicity in patients with chronic myelogenous leukemia and philadelphia positive acute lymphoblastic leukemia

  • Letter to the Editor
  • Published:
Leukemia Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1

References

  1. Goldman JM . How I treat chronic myeloid leukemia in the imatinib era. Blood 2007; 110: 2828–2837.

    Article  CAS  Google Scholar 

  2. Druker B, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N et al. Five-year follow-up of Imatinib therapy for newly diagnosed chronic myeloid leukaemia in chronic phase. N Engl J Med 2006; 355: 2408–2417.

    Article  CAS  Google Scholar 

  3. Shimoni A, Kröger N, Zander AR, Rowe JM, Hardan I, Avigdor A et al. Imatinib mesylate (STI571) in preparation for allogeneic hematopoietic stem cell transplantation and donor lymphocyte infusions in patients with Philadelphia-positive acute leukemias. Leukemia 2003; 17: 290–297.

    Article  CAS  Google Scholar 

  4. Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006; 354: 2531–2541.

    Article  CAS  Google Scholar 

  5. Kantarjian H, Giles F, Wunderle L, Bhalla K, O'Brien S, Wassmann B et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006; 354: 2542–2551.

    Article  Google Scholar 

  6. Hochhaus A, Kantarjian HM, Baccarani M, Lipton JH, Apperley JF, Druker BJ et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 2007; 109: 2303–2309.

    Article  CAS  Google Scholar 

  7. Kantarjian HM, Giles F, Gattermann N, Bhalla K, Alimena G, Palandri F et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 2007; 110: 3540–3546.

    Article  CAS  Google Scholar 

  8. Kantarjian H, O'Brien S, Talpaz M, Borthakur G, Ravandi F, Faderl S et al. Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure. Cancer 2007; 109: 1556–1560.

    Article  CAS  Google Scholar 

  9. Deininger M, Schleuning M, Greinix H, Sayer HG, Fischer T, Martinez J et al. The effect of prior exposure to imatinib on transplant-related mortality. Haematologica 2006; 91: 452–459.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel-Aviv University, Tel-Hashomer, Israel

    A Shimoni, M Leiba, M Koren-Michowitz, E Ribakovski & A Nagler

  2. Center for Bone Marrow Transplantation, Stiftung Deutsche Klinik für Diagnostik, Wiesbaden, Germany

    M Schleuning

  3. Department of Oncology, Hematology, Cell Therapy and CIC 802 INSERM, CHU La Miletrie, Poitiers, France

    G Martineau, M Renaud & F Guilhot

  4. Department of Hematology and Oncology,Charite-Universitatsmedizin, Berlin, Campus Virchow Klinikum, Berlin, Germany

    P le Coutre & R Arnold

Authors
  1. A Shimoni
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M Leiba
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M Schleuning
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G Martineau
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M Renaud
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M Koren-Michowitz
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. E Ribakovski
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. P le Coutre
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. R Arnold
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. F Guilhot
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. A Nagler
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A Shimoni.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Shimoni, A., Leiba, M., Schleuning, M. et al. Prior treatment with the tyrosine kinase inhibitors dasatinib and nilotinib allows stem cell transplantation (SCT) in a less advanced disease phase and does not increase SCT Toxicity in patients with chronic myelogenous leukemia and philadelphia positive acute lymphoblastic leukemia. Leukemia 23, 190–194 (2009). https://doi.org/10.1038/leu.2008.160

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2008.160

  • Springer Nature Limited

This article is cited by

Search

Navigation